☰
Info Tooltip

Premium Info (Not Yet Available)

Free: 3 months of data free.
Premium: Longer timeframes, improved filtering tools, no ads.

Most Recent 50 'COVID' Related ASX Announcements

These results are the type of thing you could search for in the Announcements Filter tool. In this case, we've searched for 'COVID' while 'COVID + Clinical Trial' could be a similarly interesting search.
Market SensitiveDateCompanyAnnouncement
Yes 28 Jan SPL Viraleze shows antiviral efficacy in COVID-19 patients
27 Sep ANP Publication of final Long COVID data for ATL1102
Yes 24 Sep SPL VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
Yes 15 Aug BIT COMPLETION OF PHASE 2 COVID CLINICAL TRIAL
Yes 12 May BIT Second Site Approved for Phase 2 Covid-19 Trial
Yes 03 May BIT Commencement Phase 2 Covid-19 Clinical Trial
Yes 20 Feb BIT International Presentation of BIT225 COVID-19 Data
Yes 12 Dec DXB CLARITY 2.0 COVID-19 Study Outcome
07 Dec SPL VIRALEZE Post-Market Clinical Study in COVID-19 Patients
Yes 24 Oct MXC Long COVID study Results
Yes 17 Oct RCE R327 COVID Study Update
Yes 13 Sep BIT Bit225 Covid-19 Human Study Commenced
Yes 28 Aug TYR COVID-19 Trading Update 128 - Week Ended 26 August 2022
22 Aug AT1 COVID RAT Supply Agreement signed with AllTest & TGA Update
Yes 21 Aug TYR COVID-19 Trading Update 127 - Week Ended 19 August 2022
Yes 19 Aug ANP Long Covid-19 Collaboration Outcomes Presentation
Yes 19 Aug ANP Long COVID study identifies diagnostic & therapeutic targets
Yes 17 Aug DXB CLARITY 2.0 COVID-19 Study Concludes Recruitment
Yes 14 Aug TYR COVID-19 Trading Update 126 - Week Ended 12 August 2022
Yes 07 Aug TYR COVID-19 Trading Update 125 - Week Ended 5 August 2022
Yes 31 Jul TYR COVID-19 Trading Update 124 - Week Ended 29 July 2022
Yes 24 Jul TYR COVID-19 Trading Update 123 - Week Ended 22 July 2022
Yes 17 Jul TYR COVID-19 Trading Update 122 - Week Ended 15 July 2022
Yes 14 Jul MXC Long COVID Study Results for ArtemiC Support
Yes 10 Jul TYR COVID-19 Trading Update 121 - Week Ended 8 July 2022
Yes 06 Jul CYC Technegas Used In Multicenter COVID Study
Yes 03 Jul TYR COVID-19 Trading Update 120 - Week Ended 1 July 2022
Yes 26 Jun TYR COVID-19 Trading Update 119 - Week Ended 24 June 2022
Yes 26 Jun DXB REMAP-CAP COVID-19 Study Analysis Update
Yes 19 Jun TYR COVID-19 Trading Update 118 - Week Ended 17 June 2022
Yes 13 Jun TYR COVID-19 Trading Update 117 - Week Ended 10 June 2022
Yes 05 Jun TYR COVID-19 Trading Update 116 - Week Ended 3 June 2022
Yes 31 May MDC Progression of NanoCelle NASAL COVID-19 Vaccine Program
31 May MSB Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients
Yes 29 May BIT POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
Yes 29 May TYR COVID-19 Trading Update 115 - Week Ended 27 May 2022
23 May CYC Technegas used in Diagnosing Long COVID
Yes 22 May TYR COVID-19 Trading Update 114 - Week Ended 20 May 2022
Yes 17 May ADO Updated COVID-19 RAT receives Regulatory Approval in Europe
Yes 15 May REG COVID-19 Cost Impacts and Status of Government Grants
Yes 15 May TYR COVID-19 Trading Update 113 - Week Ended 13 May 2022
Yes 08 May TYR COVID-19 Trading Update 112 - Week Ended 6 May 2022
Yes 08 May EHE Ongoing Impact of COVID-19
Yes 01 May TYR COVID-19 Trading Update 111 - Week Ended 29 April 2022
Yes 25 Apr TYR COVID-19 Trading Update 110 - Week Ended 22 April 2022
Yes 18 Apr TYR COVID-19 Trading Update 109 - Week Ended 15 April 2022
Yes 10 Apr TYR COVID-19 Trading Update 108 - Week Ended 8 April 2022
Yes 03 Apr TYR COVID-19 Trading Update 107 - Week Ended 1 April 2022
Yes 27 Mar TYR COVID-19 Trading Update 106 - Week Ended 25 March 2022
Yes 27 Mar SBM Simberi COVID-19 outbreak under control, FY22 guidance
Contact Us
Disclaimer: Our main goal is to provide you with interesting and insightful charts and metrics. Our primary goal is not data reliability, and you should assume that the data is not 100% complete or accurate. Eg. our caching system could make some data hours or days outdated, or we could run into data collection issues. This website should be used as a tool to get you thinking about a company in new ways. It should not be used to make direct investment decisions, but to help you come up with ideas which you then confirm with primary data sources. We are not liable for any data errors, omissions, delays or interuptions, or any loss arising from its use, nor do we offer financial advice.